Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase

Resistance to tyrosine kinase inhibitor (TKI) is a tough problem in the treatment of chronic myeloid leukemia in blastic phase (CML-BP), which was often associated with acquired mutations in the kinase domain and not eliminating the leukemic stem cells. The efficacy of TKI or combination with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qingya, Liang, Peiqi, Dai, Haiping, Cui, Wei, Cai, Mengjie, Ding, Zixuan, Ma, Qinfen, Yin, Jia, Li, Zheng, Liu, Sining, Kang, Liqing, Yao, Li, Cen, Jiannong, Shen, Hongjie, Zhu, Mingqing, Yu, Lei, Wu, Depei, Tang, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744919/
https://www.ncbi.nlm.nih.gov/pubmed/36524116
http://dx.doi.org/10.3389/fimmu.2022.1012981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744919/
https://www.ncbi.nlm.nih.gov/pubmed/36524116
http://dx.doi.org/10.3389/fimmu.2022.1012981

Ejemplares similares